Bronfman E.L. Rothschild L.P. boosted its stake in Astrazeneca PLC (NYSE:AZN) by 71.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,252 shares of the company’s stock after purchasing an additional 1,769 shares during the quarter. Bronfman E.L. Rothschild L.P.’s holdings in Astrazeneca PLC were worth $145,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Bank of America Corp DE increased its holdings in shares of Astrazeneca PLC by 29.5% in the 1st quarter. Bank of America Corp DE now owns 45,744,976 shares of the company’s stock worth $1,424,498,000 after buying an additional 10,414,969 shares during the last quarter. Fisher Asset Management LLC increased its holdings in shares of Astrazeneca PLC by 476.9% in the 2nd quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock worth $377,780,000 after buying an additional 9,160,764 shares during the last quarter. Primecap Management Co. CA increased its holdings in shares of Astrazeneca PLC by 32.1% in the 1st quarter. Primecap Management Co. CA now owns 34,310,950 shares of the company’s stock worth $1,068,443,000 after buying an additional 8,330,675 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Astrazeneca PLC by 287,844.0% in the 1st quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock worth $215,198,000 after buying an additional 6,908,257 shares during the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Astrazeneca PLC by 7.9% in the 1st quarter. Wellington Management Group LLP now owns 63,250,780 shares of the company’s stock worth $1,969,630,000 after buying an additional 4,605,694 shares during the last quarter. Institutional investors and hedge funds own 14.17% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Astrazeneca PLC (AZN) Stake Increased by Bronfman E.L. Rothschild L.P.” was originally published by BBNS and is owned by of BBNS. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://baseballnewssource.com/markets/astrazeneca-plc-azn-holdings-increased-by-bronfman-e-l-rothschild-l-p/1601030.html.
AZN has been the topic of a number of research reports. Goldman Sachs Group, Inc. (The) restated a “sell” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. Barclays PLC restated an “overweight” rating on shares of Astrazeneca PLC in a report on Thursday, July 13th. BMO Capital Markets began coverage on shares of Astrazeneca PLC in a report on Wednesday, September 6th. They set an “outperform” rating and a $38.00 price target on the stock. Leerink Swann downgraded shares of Astrazeneca PLC from an “outperform” rating to a “market perform” rating and cut their price target for the company from $36.00 to $31.00 in a report on Thursday, July 27th. Finally, Natixis upgraded shares of Astrazeneca PLC from a “neutral” rating to a “buy” rating in a report on Wednesday, September 6th. Four analysts have rated the stock with a sell rating, eleven have assigned a hold rating and thirteen have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $32.70.
Shares of Astrazeneca PLC (NYSE AZN) opened at 33.95 on Friday. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60. The stock has a market cap of $85.96 billion, a PE ratio of 22.27 and a beta of 0.74. The stock has a 50 day moving average of $30.33 and a 200 day moving average of $31.81. Astrazeneca PLC also saw some unusual options trading activity on Wednesday. Stock traders purchased 8,259 put options on the company. This represents an increase of 1,510% compared to the typical daily volume of 513 put options.
Astrazeneca PLC (NYSE:AZN) last released its earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.46. The company had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Astrazeneca PLC had a net margin of 17.80% and a return on equity of 35.90%. The firm’s quarterly revenue was down 9.9% on a year-over-year basis. During the same period in the prior year, the firm earned $0.83 EPS. On average, equities analysts anticipate that Astrazeneca PLC will post $1.90 earnings per share for the current fiscal year.
The business also recently disclosed a None dividend, which was paid on Monday, September 11th. Stockholders of record on Friday, August 11th were issued a dividend of $0.44 per share. The ex-dividend date of this dividend was Wednesday, August 9th. This represents a dividend yield of 2.98%. Astrazeneca PLC’s payout ratio is currently 44.92%.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with our FREE daily email newsletter.